Treatment Options for Acute Suppurative Otitis Media in Children

Acute otitis media (AOM) is one of the most common bacterial infections in early childhood, particularly affecting infants and toddlers under three years of age. Characterized by rapid onset of ear pain, fever, irritability, and often a bulging, erythematous tympanic membrane with purulent middle ear effusion, AOM requires prompt clinical assessment to guide appropriate management.

First-line treatment for confirmed bacterial AOM in otherwise healthy children remains high-dose amoxicillin—typically 80–90 mg/kg/day divided into two daily doses—for a duration of 5 to 10 days, depending on disease severity and age. For children with recurrent AOM, recent antibiotic exposure within the past 30 days, or concurrent conjunctivitis (conjunctivitis-otitis syndrome), clinicians should consider amoxicillin-clavulanate at an augmented dose (e.g., 90 mg/kg/day of amoxicillin component plus 6.4 mg/kg/day of clavulanate) to broaden coverage against beta-lactamase–producing pathogens such as *Haemophilus influenzae* and *Moraxella catarrhalis*.

Observation without immediate antibiotics—also known as “watchful waiting”—may be appropriate for select cases: children aged six months to two years with non-severe unilateral AOM and reliable follow-up, or children older than two years with mild symptoms. This approach emphasizes close monitoring and initiation of antimicrobial therapy only if clinical deterioration occurs or symptoms persist beyond 48–72 hours.

Analgesia is a critical component of management. Acetaminophen or ibuprofen should be administered regularly—not just “as needed”—to control otalgia and systemic symptoms. Topical anesthetic ear drops may provide adjunctive relief in children with intact tympanic membranes but are contraindicated if perforation or tympanostomy tubes are present.

In cases of treatment failure—defined as persistent or worsening signs and symptoms after 48–72 hours of appropriate antibiotic therapy—reassessment is essential. Options include switching to a second-line agent (e.g., cefdinir, cefpodoxime, or intramuscular ceftriaxone), evaluating for complications (e.g., mastoiditis, facial nerve palsy), or considering referral to pediatric otolaryngology for further evaluation, including possible tympanocentesis or myringotomy with tube placement in refractory or recurrent cases.